(-0.08%) 5 304.25 points
(-0.09%) 40 140 points
(-0.05%) 18 465 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(0.21%) $0.928
(0.14%) $10.86
(-0.03%) $0.792
(-0.34%) $92.26
Live Chart Being Loaded With Signals
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells...
Stats | |
---|---|
Today's Volume | 44 042.00 |
Average Volume | 44 057.00 |
Market Cap | 190.14M |
EPS | $0 ( 2024-03-27 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.880 |
ATR14 | $0.0200 (0.75%) |
Cellectis S.A. Correlation
10 Most Positive Correlations | |
---|---|
AXTI | 0.876 |
ABCL | 0.873 |
BNIXU | 0.868 |
BCOV | 0.867 |
PASG | 0.865 |
SAFT | 0.862 |
SVOK | 0.861 |
ATNI | 0.861 |
EQ | 0.855 |
GTEC | 0.854 |
10 Most Negative Correlations | |
---|---|
ASLN | -0.852 |
RDI | -0.829 |
LNTH | -0.826 |
NOVV | -0.82 |
ORTX | -0.816 |
TIG | -0.816 |
PPYAU | -0.813 |
LUNG | -0.809 |
BRIVU | -0.802 |
LINK | -0.801 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Cellectis S.A. Financials
Annual | 2022 |
Revenue: | $19.17M |
Gross Profit: | $17.40M (90.76 %) |
EPS: | $-2.17 |
Q3 | 2023 |
Revenue: | $155 000 |
Gross Profit: | $-26 000.00 (-16.77 %) |
EPS: | $-0.310 |
Q2 | 2023 |
Revenue: | $178 000 |
Gross Profit: | $123 000 (69.10 %) |
EPS: | $-0.190 |
Q1 | 2023 |
Revenue: | $139 000 |
Gross Profit: | $-195 000 (-140.29 %) |
EPS: | $-0.580 |
Financial Reports:
No articles found.
Cellectis S.A.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators